Total Payments
$62,520
2024 Payments
$9,139
Companies
13
Transactions
59
Medicare Patients
998
Medicare Billing
$208,186
Payment Breakdown by Category
Consulting$38,284 (61.2%)
Travel$12,360 (19.8%)
Research$10,147 (16.2%)
Food & Beverage$1,730 (2.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $38,284 | 12 | 61.2% |
| Travel and Lodging | $12,360 | 11 | 19.8% |
| Unspecified | $10,147 | 7 | 16.2% |
| Food and Beverage | $1,730 | 29 | 2.8% |
Payments by Type
General
$52,374
52 transactions
Research
$10,147
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $24,270 | 16 | $0 (2019) |
| Incyte Corporation | $13,144 | 13 | $0 (2024) |
| Janssen Global Services, LLC | $8,045 | 4 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $5,677 | 4 | $0 (2023) |
| PFIZER INC. | $4,570 | 4 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $2,565 | 1 | $0 (2024) |
| Spectrum Pharmaceuticals Inc. | $1,828 | 4 | $0 (2018) |
| Bayer Healthcare Pharmaceuticals Inc. | $1,745 | 4 | $0 (2023) |
| GlaxoSmithKline, LLC. | $349.21 | 3 | $0 (2018) |
| Mirati Therapeutics, Inc. | $169.31 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $9,139 | 10 | Incyte Corporation ($6,468) |
| 2023 | $13,681 | 11 | Incyte Corporation ($6,677) |
| 2022 | $100.00 | 1 | PFIZER INC. ($100.00) |
| 2021 | $1,270 | 2 | PFIZER INC. ($1,270) |
| 2020 | $1,500 | 1 | Novartis Pharmaceuticals Corporation ($1,500) |
| 2019 | $26,907 | 15 | Merck Sharp & Dohme Corporation ($17,149) |
| 2018 | $9,460 | 15 | Merck Sharp & Dohme Corporation ($7,122) |
| 2017 | $462.51 | 4 | GlaxoSmithKline, LLC. ($258.01) |
All Payment Transactions
59 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,565.00 | General |
| 10/24/2024 | Mirati Therapeutics, Inc. | — | Food and Beverage | Cash or cash equivalent | $43.41 | General |
| 10/24/2024 | Mirati Therapeutics, Inc. | — | Food and Beverage | Cash or cash equivalent | $16.56 | General |
| 09/17/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,537.50 | General |
| 09/16/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $37.81 | General |
| 06/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $46.49 | General |
| 03/28/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| 03/28/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $16.20 | General |
| 03/20/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,435.00 | General |
| 02/27/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $16.28 | General |
| 11/16/2023 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $81.28 | General |
| Category: Oncology | ||||||
| 10/24/2023 | PFIZER INC. | ELREXFIO | — | In-kind items and services | $3,200.00 | Research |
| Study: GEDATOLISIB CLINICAL PUBLICATION PROGRAM | ||||||
| 07/19/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $3,614.16 | Research |
| Study: CBYL719X2101 | ||||||
| 04/18/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $109.34 | General |
| Category: ONCOLOGY | ||||||
| 04/06/2023 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $5,901.40 | General |
| 03/31/2023 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $620.24 | General |
| 02/14/2023 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $40.53 | General |
| 01/23/2023 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $65.36 | General |
| 01/23/2023 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $16.34 | General |
| 01/23/2023 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $16.34 | General |
| 01/23/2023 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $16.34 | General |
| 06/03/2022 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $100.00 | General |
| 06/08/2021 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | ||||||
| 02/16/2021 | PFIZER INC. | — | — | In-kind items and services | $330.00 | Research |
| Study: ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | ||||||
| 01/23/2020 | Novartis Pharmaceuticals Corporation | LGK974 (Drug) | — | In-kind items and services | $1,500.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CBYL719X2101 | Novartis Pharmaceuticals Corporation | $3,614 | 1 |
| GEDATOLISIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,500 | 1 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $562.50 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 281 | 533 | $279,226 | $59,818 |
| 2022 | 5 | 240 | 435 | $216,380 | $48,870 |
| 2021 | 5 | 287 | 571 | $267,680 | $66,515 |
| 2020 | 5 | 190 | 369 | $163,148 | $32,982 |
Total Patients
998
Total Services
1,908
Medicare Billing
$208,186
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 189 | 414 | $221,024 | $45,924 | 20.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 40 | 40 | $29,925 | $5,705 | 19.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 48 | $13,684 | $4,582 | 33.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 19 | $11,399 | $2,663 | 23.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 12 | $3,194 | $943.92 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 168 | 335 | $172,659 | $38,130 | 22.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 28 | 28 | $20,158 | $4,152 | 20.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 43 | $12,169 | $3,571 | 29.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 16 | $9,253 | $2,308 | 24.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 13 | 13 | $2,141 | $709.96 | 33.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 171 | 398 | $196,566 | $47,559 | 24.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 36 | 90 | $25,470 | $7,622 | 29.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 33 | 34 | $18,146 | $5,199 | 28.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 32 | 32 | $22,547 | $4,738 | 21.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 15 | 17 | $4,951 | $1,397 | 28.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 126 | 272 | $129,744 | $23,657 | 18.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 18 | 44 | $12,452 | $3,658 | 29.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 14 | 14 | $7,270 | $2,209 | 30.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 20 | 27 | $6,354 | $1,776 | 27.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $7,328 | $1,683 | 23.0% |
About Dr. Jordi Rodon Ahnert, MD
Dr. Jordi Rodon Ahnert, MD is a Medical Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/18/2016. The National Provider Identifier (NPI) number assigned to this provider is 1841733102.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jordi Rodon Ahnert, MD has received a total of $62,520 in payments from pharmaceutical and medical device companies, with $9,139 received in 2024. These payments were reported across 59 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($38,284).
As a Medicare-enrolled provider, Rodon Ahnert has provided services to 998 Medicare beneficiaries, totaling 1,908 services with total Medicare billing of $208,186. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Medical Oncology
- Location Houston, TX
- Active Since 11/18/2016
- Last Updated 02/01/2021
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1841733102
Products in Payments
- LGK974 (Drug) $1,919
- Vitrakvi (Drug) $1,745
- INC280 (Drug) $143.25
- KRAZATI (Drug) $109.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Houston
Roy Herbst, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Putao Cen, Md, MD
Medical Oncology — Payments: $817,580
Medical Oncology $817,580
Hagop Kantarjian, Md, MD
Medical Oncology — Payments: $740,835
Medical Oncology $740,835
Dr. Matthew Ellis, Md Phd, MD PHD
Medical Oncology — Payments: $714,994
Medical Oncology $714,994
Eleni Efstathiou, M.d, M.D
Medical Oncology — Payments: $600,908
Medical Oncology $600,908
Srdan Verstovsek, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $577,763
Medical Oncology $577,763